Please use this identifier to cite or link to this item:
http://hdl.handle.net/10174/41160
|
| Title: | Innovative Drug Access in Portugal: An Analysis of Managed Entry Agreements Supporting Public Coverage 2014-2024 |
| Authors: | Costa, Paula
Advinha, Ana Margarida
Oliveira-Martins, Sofia |
| Issue Date: | 2025 |
| Citation: | Costa, P, Advinha AM, Oliveira-Martins S. Innovative Drug Access in Portugal: An Analysis of Managed Entry Agreements Supporting Public Coverage 2014-2024. In: Abstracts of the ISPOR Europe 2025. Glasgow, Scotland: Value in Health, 28(S2); 2025. HPR125. |
| Abstract: | Managed Entry Agreements (MEAs) are tools designed to reduce clinical uncertainty and mitigate budget impact of often high-cost, innovative medicines. While finance-based MEAs have been widely used, the increasing complexity of therapies has driven the adoption of more sophisticated and tailored agreements, including risk-sharing models. This study aims to characterize the MEAs established to support public coverage decisions for innovative medicines—defined as those containing new active substances—that received marketing authorization between 2014 and 2024 and obtained positive reimbursement decisions in Portugal. |
| URI: | https://www.valueinhealthjournal.com/article/S1098-3015(25)04089-6/abstract?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301525040896%3Fshowall%3Dtrue
http://hdl.handle.net/10174/41160 |
| Type: | article |
| Appears in Collections: | DCMS - Artigos em Livros de Actas/Proceedings
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|
